Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.54 |
| ▸ | HTR1A | P08908 | 7/20 | 0.54 |
| ▸ | HTR7 | P34969 | 5/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 3/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322881 | 0.94 | ADRA1D (0.62) | SLC6A4HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1323815 | 0.90 | KCNH2 (0.49) | SLC6A4HTR1AHTR6KCNH2 | |
| SCHEMBL1322812 | 0.89 | ADRA1D (0.59) | SLC6A4ADRA1D | |
| SCHEMBL1324121 | 0.85 | SLC6A4 (0.45) | SLC6A4HTR1AHTR7HTR6ADRA1D | |
| SCHEMBL13955200 | 0.85 | SLC6A4 (0.57) | SLC6A4HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1324162 | 0.85 | HTR7 (0.51) | HTR7DRD2HTR1DHTR1BCHRM2 | |
| SCHEMBL1324283 | 0.85 | GRIN2B (0.58) | HTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL1322810 | 0.83 | GRIN2B (0.48) | SLC6A4HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1322882 | 0.83 | HTR1A (0.45) | SLC6A4HTR1AHTR7HTR2AKCNH2 | |
| SCHEMBL1406345 | 0.83 | HTR1A (0.45) | SLC6A4HTR1AHTR7DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | claimed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | claimed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | claimed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | claimed |
| JP-2005523310-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| EP-1497279-A2 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GmbH (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003087086-A2 | SUBSTITUTED INDOLES | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | WO | claimed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1497279-A2 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087086-A2 | SUBSTITUTED INDOLES | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054459-A1 | Substituted indoles | TPH2, TPH1, HTR1A | SLC6A4 20/4885HTR1A 3/4885HTR7 15/4885 |
| US-20090291963-A1 | SUBSTITUTED INDOLES | TPH2, TPH1, HTR1A | SLC6A4 20/4885HTR1A 3/4885HTR7 16/4885 |
| US-20050153980-A1 | Substituted indoles | TPH2, TPH1, HTR1A | SLC6A4 20/4885HTR1A 3/4885HTR7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.